Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice guideline update

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 132-149

  Douglas Rizzo, J ^a   Somerfield, Mark R ^a   Hagerty, Karen L ^a   Seidenfeld, Jerome ^a   Bohlius, Julia ^a   Bennett, Charles L ^a   Cella, David F ^a   Djulbegovic, Benjamin ^a   Goode, Matthew J ^a   Jakubowski, Ann A ^a   Rarick, Mark U ^a   Regan, David H ^a   Lichtin, Alan E ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG MONITORING; ERYTHROPOIESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; UNITED STATES;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EPOETIN ALFA; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; HEMATINICS; HUMANS; NEOPLASMS; SOCIETIES, MEDICAL;

EID: 37849003198     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3396     Document Type: Review

References (39)

1. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
2. Food and Drug Adminstration. Oncologic Drugs Advisory Committee Briefing Document. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy. 2004. http://www.fda.gov/ohrms/dockets/ac/ 04/briefing/4037b2_04.pdf
3. Bohlius J, Wilson J, Seidenfeld J, et al: Erythropoietin or darbepetin for patients with cancer (review). The Cochrane Library Issue 2, 2007
4. Seidenfeld J, Piper M, Bohlius J, et al: Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026.) Agency for Healthcare Research and Quality, 2006. www.effectivehealthcare.ahrq.gov/reports/final.cfm
5. Wilson J, Yao GL, Raftery J, et al: A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11:1-220, 2007
6. Quirt I, Bramwell V, Charette M, et al: The Role of Erythropoietin in the Management of Cancer Patients with Non-hematologic Malignancies Receiving Chemotherapy. Cancer Care Ontario, 2007. http://www.cancercare.on.ca/pdf/pebc12- 1f.pdf
7. Shehata N, Walker I, Meyer R, et al: Treatment for Anemia with Erythropoietic Agents in Patients with non-Myeloid Hematological Malignancies: A Clinical Practicie Guideline. Cancer Care Ontario, 2007. http://www.cancercare. on.ca/pdf/pebc6-12s.pdf
8. Ross SD, Allen IE, Henry DH, et al: Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 28:801-831, 2006
9. Seidenfeld J, Piper M, Flamm C, et al: Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204-1214, 2001
10. Crawford J, Robert F, Perry MC, et al: A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2:210-220, 2007
11. Straus DJ, Testa MA, Sarokhan BJ, et al: Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 107:1909-1917, 2006
12. Rearden TP, Charu V, Saidman B, et al: Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J Clin Oncol 22:745s, 2004 (suppl, abstr 8064)
13. Lyman GH, Glaspy J: Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106:223-233, 2006
14. Browman GP: Standards of proof, standards of practice, and proof of standards: A tale of two trials. J Clin Oncol 23:2583-2585, 2005
15. Cella D, Herbst RS, Lynch TJ, et al: Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23:2946-2954, 2005
16. Cella D, Kallich J, McDermott A, et al: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 15:979-986, 2004
17. Mallinson T, Cella D, Cashy J, et al: Giving meaning to measure: Linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage 31:229-241, 2006
18. Bennett CL, Angelotta C, Yarnold PR, et al: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558-2560, 2006
19. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al: Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15:174-182, 1998
20. Thatcher N, De Campos ES, Bell DR, et al: Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80:396-402, 1999
21. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
22. Food and Drug Administration Oncologic Drugs Advisory Committee Briefing Document. Continuing Reassessment of the Risks of Erythropoiesis-Simulating Agents (ESAs) Administered for the Treatment of Anemia associated with Cancer Chemotherapy. 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2- 02-FDA.pdf
23. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 103:1070-1074, 1998
24. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
25. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
26. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032, 2007
27. Khuri FR: Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356:2445-2448, 2007
28. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307, 2004
29. Henry DH, Dahl NV, Auerbach M, et al: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231-242, 2007
30. Hedenus M, Birgegard G, Nasman P, et al: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 21:627-632, 2007
31. Casadevall N, Durieux P, Dubois S, et al: Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104:321-327, 2004
32. Abels RI, Larholt KM, Krantz KD, et al: Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer. Oncologist 1:140-150, 1996
33. Charu V, Belani CP, Gill AN, et al: Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: A controlled, randomized, open-label phase II trial. Oncologist 12:727-737, 2007
34. Gordon DH, Nichols G, Ben-Jacob A, et al: Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy. Blood 108:328a, 2006 (abstr 1304)
35. Mystakidou K, Kalaidopoulou O, Katsouda E, et al: Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 25:3495-3500, 2005
36. Smith RE Jr, Tchekmedyian NS, Chan D, et al: A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851-1858, 2003
37. Danish Head and Neck Cancer Group (DAHANCA). Study of the importance of Novel Erthropoiesis Stimulating Protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carinoma of the head and neck. 2006.http://www.dahanca.dk/get_media_file.php?mediaid=125
38. Hedenus M, Adriansson M, San Miguel J, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403, 2003
39. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006